2cureX AB (OSTO:2CUREX) ROCE % : -164.03% (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 2cureX AB's annualized ROCE % for the quarter that ended in Sep. 2023 was -164.03%.

2cureX AB ROCE % Historical Data

The historical data trend for 2cureX AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB ROCE % Chart

2cureX AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-49.83

-44.46

-19.21

-33.59

-50.73

2cureX AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-54.68	-40.39	-85.85	-110.16	-164.03

2cureX AB ROCE % Calculation

2cureX AB's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-29.77	/	( ( (79.16 - 4.816)	+	(47.657 - 4.623) )	/ 2 )
	=	-29.77	/	( (74.344	+	43.034)	/ 2 )
	=	-29.77	/	58.689
	=	-50.73 %

2cureX AB's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-36.992	/	( ( (29.765 - 2.403)	+	(21.483 - 3.74) )	/ 2 )
	=	-36.992	/	( ( 27.362	+	17.743 )	/ 2 )
	=	-36.992	/	22.5525
	=	-164.03 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

2cureX AB (OSTO:2CUREX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

2cureX AB ROCE % Related Terms

Thank you for viewing the detailed overview of 2cureX AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

2cureX AB (OSTO:2CUREX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2QE:Germany

Address

Fruebjergvej 3, Copenhagen, DNK, DK-2100

Website

https://www.2curex.com

2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines